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ABSTRACT 
 
Background: Drug transporters have been increasingly recognized as important 
determinants of variable drug disposition and response. For the pharmaceutical industry it is 
of importance to develop in vitro models, which could predict possible transporter-associated 
genetic variability and drug-drug interactions of a new compound. The purpose of this study 
was to compare uptake kinetics of estradiol-17β-D-glucuronide, atorvastatin and pravastatin 
in three in vitro models expressing the membrane drug transporter OATP1B1.  
 
Methods: Two in vitro models overexpressing OATP1B1 were applied in this study; HEK293 
cells transfected with the gene encoding OATP1B1 and Xenopus laevis oocytes injected with 
OATP1B1 cDNA. HEK293 cells transfected with the empty vector pT-REX and water injected 
oocytes were used as control systems. HepaRG cells, the third model applied in this study, 
express naturally occurring levels of OATP1B1 and other transporters, and studies at 4°C 
were used as control. Uptake studies were performed with three known substrates for 
OATP1B1; estradiol-17β-D-glucuronide, atorvastatin and pravastatin. Time- and 
concentration dependent uptake was studied. Km values were estimated by non-linear 
regression analysis of the active uptake calculated in concentration dependence studies. The 
active uptake was calculated as the difference between intrasystemic accumulation of test 
substance in the model system and in the respective control system.  
 
Results: Estradiol-17β-D-glucuronide exhibited active uptake in all time- and concentration 
dependence uptake studies performed on the three models. The active transport of estradiol-
17β-D-glucuronide was saturated in the concentration dependence studies, with estimated Km 
values of 5.6 ± 0.3 μM, 5.9 ± 3.8 μM and 22.3 ± 7.1 μM in HEK293 cells, oocytes and 
HepaRG cells, respectively. Atorvastatin showed active uptake in all time dependence uptake 
studies. In the concentration dependence uptake studies, atorvastatin exhibited no active 
uptake in HEK293 cells and oocytes, while in the HepaRG cells, a non-saturated active 
uptake was demonstrated. In the time dependence uptake studies with pravastatin, an active 
uptake was shown in HEK293 and HepaRG cells, while a limited active uptake was 
demonstrated in the oocytes. On the contrary, concentration dependence uptake studies 
showed no active uptake of pravastatin in HEK293 and HepaRG cells, but a saturated active 
uptake in oocytes with estimated Km value of 54.8 ± 31.4 μM. 
 
Discussion and conclusion: Estradiol-17β-D-glucuronide was the only substrate showing 
consistent time- and concentration dependent results in all tested models.  Results from the 
studies with atorvastatin and pravastatin were inconsistent between the models. Furthermore, 
concentration dependence and saturation of uptake was difficult to obtain even if a time 
dependent uptake was recorded. The inconsistent results with atorvastatin and pravastatin 
could be due to the higher lipophilicity and greater extent of passive diffusion compared to 
7 
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estradiol-17β-D-glucuronide. It could therefore be hypothesized that when a substrate exhibits 
greater passive diffusion than active uptake, the models would not be sufficiently sensitive to 
separate the active uptake from the passive uptake. As drugs are generally more lipophilic 
than estradiol-17β-D-glucuronide, none of the in vitro transport models studied are expected 
to be appropriate for routine screening of new drugs as possible substrates for OATP1B1.  
 
INTRODUCTION 
1 INTRODUCTION 
1.1 Background 
Pharmacokinetics refers to the processes of drug absorption, distribution, metabolism and 
elimination, while pharmacodynamic processes involve the mechanisms of drug action. Drug 
efficacy reflects the interplay of pharmacokinetics and pharmacodynamics (Buxton, 2006).   
 
In drug development, it is of importance to reveal which pharmacokinetic processes that 
determine the systemic drug exposure. Most studies to date have focused on metabolizing 
enzymes and filtration in the kidneys as pharmacokinetic variables causing interindividual 
differences in drug exposure (Gonzales and Tukey, 2006). Drug-metabolizing reactions are 
classified into phase I and phase II. Phase I reactions involves oxidation, reduction or 
hydrolysis of the drug, and are primarily mediated by the cytochrome P450 family of enzymes. 
Phase II reactions involve covalently binding of an endogenous compound, most often 
glucuronide acid, glutathione or sulfate, to the phase I-metabolite. This conjugation produces 
a more polar metabolite and promotes excretion of the drug (Gonzales and Tukey, 2006; Ho 
and Kim, 2005).  
 
Most pharmacokinetic processes involve drug passage across cell membranes, even 
metabolism. Drugs require transport into intestine and/or liver cells, to be susceptible to 
metabolism. Physiochemical properties of a drug that determine its movement and access to 
target tissue are molecular size and shape, pKa, lipophilicity and binding to serum and tissue 
proteins. Passive diffusion through the membrane has been viewed as dominant in the 
disposition of most drugs (Buxton, 2006), but it is now increasingly recognized that carrier-
mediated transport have a significant impact on the absorption, distribution and elimination of 
the drug (Ho and Kim, 2005; Kim, 2006; Ware, 2006; Yamazaki et al., 2005). Interindividual 
variability in carrier-mediated transport, due to inheritable differences in the genes encoding 
specific transporters or drug-drug interactions, may be an important cause of abnormal drug 
exposure and response. 
 
For the pharmaceutical industry it is of importance to develop in vitro models, which could 
predict possible genetic variability and drug-drug interactions of a new compound associated 
to active transport. A transporter of particular interest is the organic anion transporting 
polypeptide 1B1 (OATP1B1), which is located in the blood-liver interface and believed to be 
important in hepatic clearance of several drugs (Lau et al., 2004; Sasaki et al., 2004; Smith et 
al., 2005; Yamazaki et al., 1996). 
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1.2 Membrane transporter families 
Two major gene superfamilies play a prominent role in the transport of drugs across biological 
membranes; the solute carrier (SLC) superfamily and the ATP-binding cassette (ABC) 
superfamily (Giacomini and Sugiyama, 2006). The members of the SLC superfamily are 
uptake transporters, and the most important subfamilies involved in disposition of drugs are 
the organic anion transporting polypeptide (OATP) family, the organic anion transporter (OAT) 
family and the organic cation transporter (OCT) family (Kim, 2006). The members of the ABC 
superfamily are efflux transporters, using energy released from ATP hydrolysis to transport 
substrates out of cells (Davidson and Maloney, 2007). The most important proteins involved 
in this transport are P-glycoprotein (P-gp/MDR-1), multidrug resistance associated protein 2 
(MRP2), bile salt exporting pump (BSEP) and breast cancer resistance protein (BCRP) (Kim, 
2006). 
1.2.1 The OATP family 
The human OATP family consists of 11 members, where all share a similar transmembrane 
domain organisation with 12 predicted domains (Figure 1.1) (Hagenbuch and Meier, 2004; 
Meier et al., 1997). The OATPs are expressed in multiple tissues, including the intestine, liver, 
kidney and brain, where they mediate the sodium-independent transport of a wide variety of 
substrates, i.e. bile salts, hormones and steroid conjugates (Abe et al., 1999; Kakyo et al., 
1999; Konig et al., 2006). 
 
 
Figure 1.1 Structure of the OATP transporters which all consist of 670 amino acids with 12 putative transmembrane 
domains. All seven potential N-linked glycosylation sites are located on the same side of the membrane suggesting 
that both the N- and C-terminal of the protein are situated within inside the cell (Meier et al., 1997). 
1.2.2 OATP1B1 
OATP1B1 (formerly OATP-C, OATP2, LST-1; gene symbol SLCO1B1) belongs to the 
OATP1B subfamily of the OATP family. OATP1B1 is expressed primarily in the liver, and is 
localised primarily to the basolateral membrane of hepatocytes (Figure 1.3) (Hsiang et al., 
1999; Konig et al., 2000). In the addition to transport of endogenous substances (e.g. bile 
salts, steroids, leukotriene C4 and thyroid hormone), OATP1B1 is capable of transporting 
10 
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various xenobiotics and drugs into hepatocytes, facilitating the hepatocellular accumulation of 
these substrates prior to metabolism and/or excretion into bile (Figure 1.3) (Hsiang et al., 
1999). Estradiol-17β-D-glucuronide (Figure 1.2) and estrone sulfate are extensively studied 
probe substrates for the OATP1B1 transporter (Iwai et al., 2004; Konig et al., 2000; 
Matsushima et al., 2005; Nakai et al., 2001; Nozawa et al., 2002; Sasaki et al., 2004; Sasaki 
et al., 2002).  
OH
OC
OH
OH
O
OHCH3
O
OH
 
Figure 1.2 Chemical structure of estradiol-17β-D-glucuronide. 
 
Other OATP1B1 substrates include pravastatin (Hsiang et al., 1999; Nakai et al., 2001) and 
atorvastatin (Kameyama et al., 2005). Ciclosporine A, rifampicin and gemfibrozil have all been 
reported to inhibit the transport function of OATP1B1 in vitro (Nakagomi-Hagihara et al., 2007; 
Noe et al., 2007; Schneck et al., 2004; Shitara et al., 2004a; Shitara et al., 2004b; Tirona et 
al., 2003), introducing the risk of drug-drug interactions following co-administration with 
OATP1B1 substrates (Nakagomi-Hagihara et al., 2007; Noe et al., 2007; Schneck et al., 
2004; Shitara et al., 2004a; Shitara et al., 2004b). 
 
 
Figure 1.3 Uptake and efflux transporters and their localization in human hepatocytes (OATP1B1 is expressed by the 
former name OATP-C) (Marzolini et al., 2004). 
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Polymorphisms in genes encoding transport proteins may play an important role in the 
interindividual variability of drug disposition and drug response. A number of single nucleotide 
polymorphisms (SNPs) and haplotypes of SLCO1B1 have been reported (Figure 1.4) 
(Michalski et al., 2002; Nishizato et al., 2003; Nozawa et al., 2002; Pasanen et al., 2006; 
Rohrbacher et al., 2006; Tirona et al., 2001).  
 
Figure 1.4 Localisation of amino acid exchanges caused by mutations in genes encoding human members of the 
OATP family. Mutations in the SLCO1B1 gene encoding OATP1B1 are shown in red (Konig et al., 2006). 
 
The SNP 521T>C is commonly existing in four major haplotypes of OATP1B1. Of these 
haplotypes, at least *5, *15 and *17 have been associated with increased plasma 
concentrations of various statins (Chung et al., 2005; Lee et al., 2005; Mwinyi et al., 2004; 
Niemi et al., 2004), suggesting that the 521T>C SNP determines the functional properties of 
these OATP1B1 haplotypes. At the molecular level, the reduced OATP1B1 transport function 
may be explained by defects in cell surface trafficking of the transporter protein (Kameyama 
et al., 2005; Tirona et al., 2001). 
1.3 HMG-CoA reductase inhibitors 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely 
used lipid-lowering drugs. Statins inhibit the synthesis of mevalonate in hepatocytes, the rate-
limiting step in cholesterol biosynthesis, leading to a reduction in the plasma low density 
lipoprotein (LDL)-cholesterol level. High plasma LDL-cholesterol is a risk factor of 
cardiovascular diseases, and statins are used extensively in the clinic to prevent progression 
of atherosclerosis. Myopathy is an adverse effect of all statins, but the most severe form of 
myotoxicity, rhabdomyolysis, is rare with currently used statins (Bays, 2006; Cziraky et al., 
2006; Graham et al., 2004). High statin doses, as well as certain drug-drug interactions, 
particularly those leading to high statin concentrations in peripheral blood and muscle cells, 
increase the risk of myotoxicity (Abdul-Ghaffar and el-Sonbaty, 1995; Chang et al., 2004; 
Knoll et al., 1993; Maxa et al., 2002; Pierce et al., 1990; Pogson et al., 1999; Tal et al., 1997). 
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Because of their extensive clinical use, the likelihood that new drugs would be co-
administered with statins is high. Therefore, the drug-drug interaction potential with statins is 
of great importance for the clinical safety of new drug candidates.  
 
The statins enter the hepatocytes by both passive and active transport (Shitara and 
Sugiyama, 2006). The extend of passive uptake is varying according to the lipophilicity of the 
statin (Shitara and Sugiyama, 2006). The active uptake into hepatocytes are mediated 
primarily by the OATP1B1 transporter (Shitara and Sugiyama, 2006). Atorvastatin, 
pravastatin, cerivastatin, pitavastatin and rosuvastatin are all reported to be substrates of 
OATP1B1, with pravastatin and atorvastatin as the most extensively studied agents (Fujino et 
al., 2004; Hsiang et al., 1999; Kameyama et al., 2005; Lau et al., 2006; Nakai et al., 2001; 
Schneck et al., 2004; Shitara et al., 2003a).  
 
Most statins are administered as the orally active β-hydroxy acid form, except from lovastatin 
and simvastatin (Shitara and Sugiyama, 2006). Observation of both acid and lactone forms in 
the systemic circulation after administration of atorvastatin, lovasatatin, simvastatin and 
cerivastatin indicates an interconversion between the acid and lactone forms of these statins 
(Kantola et al., 1998a; Kantola et al., 1998b; Neuvonen and Jalava, 1996; Prueksaritanont et 
al., 2002). Chen et al examined the interaction of statins (pravastatin, atorvastatin acid an 
lactone, simvastatin acid and lactone, lovastatin acid and lactone) with P-gp, MRP2 and 
OATP1B1, and observed that the the IC50 values for the P-gp and MRP2 for all statins in acid 
form were up to 10-fold lower than for the corresponding lactone (Chen et al., 2005). In 
contrast, inhibition of OATP1B1 by these statins showed that the acid form was more potent 
than the lactone form, with an IC50 value 3- to 7-fold lower for the acid form (Chen et al., 
2005).  
1.3.1  Pravastatin 
Pravastatin is administered as the open acid form (Figure 1.5). Pravastatin has a high affinity 
for HMG-CoA reductase with inhibition constant (Ki) of 44.1 nM (McTaggart et al., 2001). The 
logD value (pH 7.0) of pravastatin is –0.47 (Ishigami et al., 2001), indicating limited 
membrane permeability and low passive diffusion. Pravastatin is actively transported from the 
portal blood into hepatocytes by OATP1B1 (Hsiang et al., 1999; Nakai et al., 2001). 
Pravastatin is not significantly metabolized by the cytochrome P-450 enzymes (Hatanaka, 
2000), and biliary excretion is a major route of elimination. The excretion into the bile is 
mediated by several efflux transporters; MRP2, P-gp, BCRP and BSEP (Figure 1.3) (Hirano 
et al., 2005; Matsushima et al., 2005; Sasaki et al., 2002). MRP2 has the highest transport 
activity (Matsushima et al., 2005). 
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Figure 1.5 Chemical structure of the open acid form of pravastatin. 
 
Expression and function of OATP1B1 is considered the rate-limiting step in the hepatic 
clearance of pravastatin (Yamazaki et al., 1996). Altered systemic exposure of pravastatin as 
a result of transporter-mediated drug-drug interactions or SLCO1B1 polymorphisms could 
therefore change the clinical response. Although pravastatin is not involved in P450-mediated 
drug-drug interactions, it is likely to be affected by transporter-mediated drug-drug interactions 
when co-administration with inhibitors of OATP1B1 (Kyrklund et al., 2003; Nakagomi-
Hagihara et al., 2007; Seithel et al., 2007; Yamazaki et al., 2005). Nakagoni-Hagihara et al 
showed that when pravastatin was co-administrated with the OATP1B1 inhibitor gemfibrozil, 
the AUC of pravastatin increased approximately 2-fold (Nakagomi-Hagihara et al., 2007). The 
same results were reported by Kyrklund et al. (Kyrklund et al., 2003). 
 
Effects of the SLCO1B1 polymorphisms on the transport activity in vitro and on the 
pharmacokinetics in human have been investigated in recent studies. The SLCO1B1 *5, *15 
and *17 haplotypes are associated with increased plasma concentration of pravastatin 
(Mwinyi et al., 2004; Niemi et al., 2005; Niemi et al., 2004; Nishizato et al., 2003). Niemi et al 
showed that AUC of pravastatin increased with 93% and 130% in heterocygote carriers of *15 
and *17, respectively, compared to subjects with reference haplotype (Niemi et al., 2004). In 
addition, 521T>C polymorphism is associated with reduced total colesterol-lowering effect of 
pravastatin (Niemi et al., 2005; Tachibana-Iimori et al., 2004; Zhang et al., 2006). Zhang et al. 
showed an attenuated total colesterol-lowering effect in patients with 521TC heterozygote 
genotype (-14.5% reduction), compared to 521TT homocygote genotype (-22.4% reduction) 
(Zhang et al., 2006). On the conterary, the SLOO1B1 *1b haplotype, is associated with 
decreased plasma concentration of pravastatin (Maeda et al., 2006; Mwinyi et al., 2004). 
Mwinyi et al. reported that AUC of pravastatin was 35% lower in subjects carrying the *1b 
haplotype than in the subjects with *1a/*1a reference genotype (Mwinyi et al., 2004).  
 
The myotoxic effects of statins are concentration-dependent (Thompson et al., 2003), and 
subjects with increased plasma concentration of pravastatin due to transporter-mediated 
drug-drug interactions or certain polymorphisms in the gene encoding OATP1B1, are more 
susceptible to pravastatin-induced myopathy (Ballantyne et al., 2003; Biggs et al., 2006; 
Chang et al., 2004; Graham et al., 2004; Omar et al., 2001; Regazzi et al., 1993; Schindler et 
14 
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al., 2007). Morimoto et al. found that the frequency of SLCO1B1 *15 is significantly higher in 
patients who experienced myopathy after receiving pravastatin or atorvastatin than in patients 
without myopathy (Morimoto et al., 2004). 
1.3.2 Atorvastatin 
Atorvastatin is administered as the open acid form (Figure 1.6). Atorvastatin has higher 
affinity for HMG-CoA reductase than pravastatin with an inhibition constant (Ki) of 8.2 nM 
(McTaggart et al., 2001). The logD value (pH 7.0) of atorvastatin is 1.53 (Ishigami et al., 
2001), indicating that atorvastatin undergoes passive diffusion to a greater extent than 
pravastatin. Atorvastatin is also a substrate of OATP1B1 and enters the hepatocytes via 
carrier-mediated uptake (Chen et al., 2005; Kameyama et al., 2005; Lau et al., 2007; Lau et 
al., 2006). In hepatocytes atorvastatin are predominantly metabolized by cytochrome P450 
3A4 (CYP3A4) (Lennernas, 2003). Atorvastatin is also excreted into bile by P-gp and MRP2 
(Chen et al., 2005; Lau et al., 2006). 
N
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Figure 1.6 Chemical structure of the open acid form of atorvastatin. 
 
The clearance of atorvastatin is affected by both the metabolic rate and the uptake rate 
(Shitara and Sugiyama, 2006), which implies susceptibility to CYP3A4- as well as OATP1B1-
mediated drug-drug interactions (Lau et al., 2007; Lau et al., 2006; Lau et al., 2004; 
Lennernas, 2003; Åsberg et al., 2001). Lau et al. reported that co-administration with 
rifampicin acutely increased the AUC of atorvastatin around 6-fold (Lau et al., 2007). This was 
explained as an inhibitor effect of the OATP1B1 transporter. Hermann et al. showed a 10-fold 
increase in AUC of atorvastatin in patients treated with ciclosporine (Hermann et al., 2004), 
possibly due to inhibition of OATP1B1. 
 
Like pravastatin, SLCO1B1 polymorphisms can cause interindividual differences in plasma 
concentrations of atorvastatin (Kameyama et al., 2005; Pasanen et al., 2007). Pasanen et al. 
reported that subjects with the SLCO1B1 521CC genotype had a 144% or 61% higher AUC of 
atorvastatin than those with the 521TT or 521TC genotype, respectively (Pasanen et al., 
2007).  
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The myotoxic effects of statins are concentration-dependent (Thompson et al., 2003), and 
subjects with increased plasma concentration of atorvastatin due to drug-drug interactions or 
certain polymorphisms in the gene encoding OATP1B1, are more susceptible to atorvastatin-
induced myopathy (Ballantyne et al., 2003; Graham et al., 2004; Omar et al., 2001). As 
mentioned in section 1.3.1, Morimoto et al. found that the frequency of SLCO1B1 *15 is 
significantly higher in patients who experienced myopathy after receiving pravastatin or 
atorvastatin than in patients without myopathy (Morimoto et al., 2004). On the contrary, 
Hermann et al. reported no differences in frequencies of SLCO1B1, MDR1, and CYP3A5 
polymorphisms between patients with atorvastatin-related myopathy and the control group 
(Hermann et al., 2006). This study also showed that the exposure of atorvastatin was 
unchanged, but the lactone and acid metabolites were increased several-fold in patients with 
atorvastatin-induced myopathy.   
1.4 In vitro transport systems 
For the pharmaceutical industry it is of importance to develop in vitro transport models with 
the ability to predict possible genetic variability and drug-drug interactions of a new 
compound. This is valuable information in an early stage of drug development when 
determining whether a compound should be included in further trial, and if so, the clinical 
pharmacokinetic studies that should be performed. In vitro transport models are also 
important tools when determining pharmacokinetic characteristics of existing, uncharacterized 
drugs. 
 
A variety of different model systems have been applied to characterize the mechanisms of 
drug transport and estimate the elimination rates of drugs via liver. Isolated hepatocytes are 
often used as model system, and recent progress in cryopreservation techniques have 
enabled preservation of frozen human hepatocytes in a way that most of their transporter 
activity is retained (Shitara et al., 2003b). Membrane vesicles prepared from the sinusoidal 
and bile canalicular membrane in the liver are readily available for the study of hepatobiliary 
transport, but a possible limitation of the model system is the requirement of a driving force for 
transport (i.e. ATP hydrolysis) (Shitara et al., 2005). Transfected cell systems expressing a 
specific transporter are used to obtain the kinetic parameters for the target transporter. cDNA 
transfected cells or cRNA injected oocytes can be used as gene expression systems. More 
recently, cultured cells stably transfected with both uptake and efflux transporters have 
become available. In these systems, transcellular transport of a compound can be measured. 
As human tissue samples are scarcely distributed, the transporter-expressing systems are 
valuable tools in drug transport studies (Shitara et al., 2005).  
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1.4.1 HEK293 cells 
Human embryonic kidney (HEK) cells are extensively used as an expression tool for 
recombinant proteins (Thomas and Smart, 2005). For transport studies, HEK293 cells are 
transfected with a gene encoding a transport protein of interest. The result of the transfection 
is a HEK293 cell line overexpressing the specific transport protein. Transfected HEK293 cells 
are widely used because of its easy reproduction and maintenance, ability of transfection 
using a wide variety of methods, high efficiency of transfection and protein production, and 
reliable translation and processing of proteins (Thomas and Smart, 2005). HEK293 cells grow 
in epithelial-like monolayers and have become increasingly recognized as models for 
transporter studies. HEK293 cells transfected with a plasmid containing the SLCO1B1 gene is 
a cell line expressing the transport protein OATP1B1.These cells are simple cell systems 
overexpressing OATP1B1. HEK293 cells transfected with the empty vector pT-REX can be 
used as control cells in transport studies with HEK293/OATP1B1 cells. 
1.4.2 Xenopus laevis oocytes 
Xenopus laevis oocytes are oocytes obtained from a frog in the genus Xenopus. The ease of 
manipulations in the embryos has given them an important place in developmental biology. 
cRNA encoding the protein of interest is injected into Xenopus laevis oocytes, leading to the 
expression of the specific transporter. Xenopus laevis oocytes injected with cRNA encoding 
OATP1B1 is a simple transport system overexpressing OATP1B1. Water injected Xenopus 
laevis oocytes can be used as control system in transport studies with OATP1B1 cRNA 
injected oocytes. 
1.4.3 HepaRG cells 
HepaRG cells are cells derived from a human hepatocellular carcinoma (Le Vee et al., 2006). 
This is a cell system expressing naturally occurring levels of a mixture of transporters and 
enzymes. HepaRG cells have the unique properties of maintaining significant levels of 
hepatocytes functions, including enzyme and transporter activity (Aninat et al., 2006; Le Vee 
et al., 2006). HepaRG cells can be grown in monolayers, which make them suitable for 
uptake studies. Compared to the transport models described above (1.4.1, 1.4.2), this is a 
complex cell system with retained transporter and enzyme multiplicity. 
1.5 Transport kinetics 
Drugs cross membranes either by passive or active, carrier-mediated processes. The total 
transport of a drug into the cell, Utotal, can be expressed as: 
passiveactivetotal UUU +=  (Equation 1.1) 
, where Uactive is the active uptake of the drug mediated by carriers, and Upassive is the passive 
diffusion of the drug across the membrane. 
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Active uptake transport is similar to enzyme-catalyzed reactions, and the Michaelis-Menten 
model can be used to determine uptake kinetics of drug transport through membrane drug 
transporters. The relationship between transport protein and substrate can be expressed as:  
21 STTSST +→↔+  
, where T is the transport protein, TS is the complex of transport protein and substrate, S1 and 
S2 are the substrates on side 1 respectively side 2 of the membrane. The initial velocity 
(V0_total) of a transport process at steady state, including active and passive transport, at a 
given substrate concentration (S), is given by the modified Michaelis-Menten equation: 
[ ]
[ ] [ ]SPSK
SVV
m
total += max_0  (Equation 1.2) 
, where Vmax is the maximum velocity of the transport process under given conditions, Km is 
the Michaelis constant, and P is the constant describing passive diffusion. The initial velocity 
of the passive diffusion, V0_passive, at a given substrate concentration (S), is expressed as: 
[ ]SPV passive ×=_0   (Equation 1.3) 
, where P is the constant describing passive diffusion. Equation 1.1-1.3 gives an expression 
of the initial uptake rate of the carrier-mediated uptake, V0_active, at a given substrate 
concentration (S): 
[ ]
[ ]SK
SV
V
m
active
max
_0 =   (Equation 1.4) 
, where Vmax is the maximum velocity of the transport process under given conditions and Km 
is the Michaelis constant. This is the Michealis-Menten equation. Equation 1.2, 1.3 and 1.4 
are illustrated in Figure 1.7 for compounds exhibiting low and high passive diffusion. Equation 
1.2, 1.3 and 1.4 are illustrated as the total, passive and active uptake, respectively. 
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Figure 1.7 Total, passive and active uptake of a drug exhibiting low passive diffusion (A) and high passive diffusion 
(B). 
 
The Michaelis constant, Km, is defined as the [S] at ½ Vmax (Figure 1.8). Km is an expression 
of the substrate affinity for the transporter. A low Km corresponds to a high affinity. Vmax is an 
expression of the capacity of the process. 
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Km
Vmax
½ Vmax
[S]  
Figure 1.8 The uptake kinetics of an actively transported compound following the Michaelis-Menten kinetics. Km 
represents the Michaelis constant, the substrate concentration at which the initial uptake rate is half maximal. 
 
The initial velocity/uptake rate is given by: 
12
12
0 tt
UUV −
−=   (Equation 1.5) 
, where t1 and t2 are two early points of time within the linear interval of uptake, and U1 and U2 
are uptake at t1 and t2 respectively.  
 
To apply the Michaelis-Menten equation (Equation 1.4), the time point chosen has to be 
within the linear interval of uptake. A low and high concentration is chosen, and uptake is 
measured against time. According to these results, a point of time is chosen where the initial 
uptake rate at both concentrations is within the linear interval. This time of incubation is 
applied in the further concentration dependence uptake studies. 
 
Co-incubation of inhibitor and substrate of a certain membrane transporter changes the 
uptake kinetics of the substrate. The presence of a constant concentration of a competitive 
inhibitor affects the affinity by increasing Km, while Vmax remains constant. Uncompetitive 
inhibitors affect the uptake kinetics by decreasing both Vmax and Km. Non-competitive 
inhibitors decrease the capacity of the process (Vmax), while Km is not affected.    
1.6 Purpose of the study 
The purpose of the present study is to evaluate and compare three existing in vitro models 
expressing the membrane drug transporter OATP1B1. Two of the models are simple systems 
overexpressing OATP1B1, while the third one is a human cell line expressing natural levels of 
OATP1B1, in addition to other transport proteins and enzymes found in human hepatocytes. 
Uptake studies of three known substrates for OATP1B1, estradiol-17β-D-glucuronide, 
atorvastatin and pravastatin, will be applied to compare the systems.  
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2 MATERIALS AND METHODS 
2.1 Materials 
3H-estradiol-17β-D-glucuronide (53 Ci/mmol, 46.9 Ci/mmol) was purchased from PerkinElmer 
(Boston, MA, USA). 3H-atorvastatin (5 Ci/mmol) was purchased from American Radiolabeled 
Chemicals Inc. (St Louis, MO, USA). 3H-pravastatin (20 Ci/mmol) was purchased from 
Moravek Biochemicals (Brea, CA, USA). Atorvastatin calcium and pravastatin sodium were 
purchased from Toronto Research Chemical Inc. (Toronto, Canada). Dimethylsulfoxide 
(DMSO) and estradiol-17β-D-glucuronide were purchased from Sigma-Aldrich (Steinheim, 
Germany). D-MEM/F-12 (1:1) (1x) liquid with GlutaMAXTM I, D-PBS without CaCl2 and MgCl2 
(D-PBS--), foetal calf serum (FCS), geneticin (G418, 50 mg/ml), Hanks balanced salt solution 
(HBSS) with CaCl2 and MgCl2, HEPES (1 M), L-glutamine (200 mM), PEST (Penicillin (100 
U/ml)-Streptomycin (100 μg/ml)-solution), and Trypsin-EDTA (1x) 0.05 % with EDTA 4Na, 
were purchased from Gibco/Invitrogen (Paisley, UK). DHI Medium was purchased from SAFC 
Biosciences (Andover, UK). Sodium butyrate was purchased from Merck (Schuchardt, 
Germany). HepaRG medium containing DMSO and basal HepaRG medium were purchased 
from Biopredic International (Rennes, France). Sodium transport buffer, ND96 buffer and 10% 
SDS buffer were purchased from BD Biosciences (Woburn, MA, USA). SuperScript III First-
Strand Synthesis System for RT-PCR and Trizol reagent were acquired from Invitrogen 
(Stockholm, Sweden). The primers and probe used in this study were provided by Applied 
Biosystems (Cheshire, UK). Taqman Assay on Demand and Taqman® Universal Master Mix 
were purchased from Applied Biosystems (Stockholm, Sweden). All other chemicals were of 
analytical grade and highest quality available. 
2.2 Cell culturing and seeding 
2.2.1 HEK 293 cells 
HEK293 cells stably transfected with human OATP1B1 and HEK293 cells stably transfected 
with empty vector (pT-REX) were obtained from the GADGET project at AstraZeneca 
Södertälje/Lund.  
 
The culture medium was composed of 500 ml DHI Medium, 58 ml heat-inactivated FCS 
(Foetal Calf Serum), 6 ml 200 mM L-glutamine, 6 ml 180 mM sterile stock solution of CaCl2 
and 6 ml 50 mg/ml stock solution of geneticin. The HEK293 cells were grown in 75cm2 plastic 
culture flasks NunClonTM Surface (NuncTM, Roskilde, Denmark) at 37°C in a humid 
atmosphere (5% CO2), CO2 incubator (LabRum Klimat AB, Stockholm Sweden). The culture 
medium was changed every 2-3 days. 
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The cells were split into a new passage approximately twice a week at 70-80% confluence. 
Old medium was removed by aspiration, and the cells were washed with 5 ml D-PBS--. 2 ml 
trypsin/EDTA (0.05%) was added. The flask was gently shaken after approximately 1 minute 
to detach the cells, and the cells were collected in a centrifuge tube containing 10 ml pre-
heated (37°C) culture medium. The tube was centrifuged 4 minutes at 800 rpm (Centrifuge 
Rotina 24TM, Hettich, Germany). The supernatant was removed from the cells, and the pellet 
was resuspended in 20 ml pre-heated medium. The cells were counted in the 
NucleoCounter® (ChemoMetec A/S, Denmark). Approximately 3 million cells were seeded 
into new 75 cm2 flasks containing 10 ml culture medium, and grown for approximately 4 days 
before new splitting or seeding on plates. 
 
For uptake studies, the HEK293 cells were seeded in poly-D-lysine coated 24-well cell culture 
plates at 0.3 million cells per well (BD BioCoat TM Multiwell Cell Culture Plates, BD 
Bioscience), and incubated for 72 hours before experimentation. 
 
The conditions described above were chosen after initial testing of conditions in uptake 
studies performed on estradiol-17β-D-glucuronide, the model substrate for OATP1B1. This 
was performed due to deviations from previously reported Km values of estradiol-17β-D-
glucuronide (Iwai et al., 2004; Konig et al., 2000) in preliminary experiments. The following 
cell culturing conditions were tested and evaluated; 
− Another culture medium consisting of 500 ml D-MEM/F-12 (1:1) (1x) liquid with 
GlutaMAXTM I, 50 ml heat-inactivated FCS, 2.5 ml PEST and 5 ml Geneticin (50 mg/ml) 
was used.  
− 1 million HEK293 cells were seeded into 75 cm2 flasks with 25 ml of the culture medium 
above, and grown for 7 days before sub cultivation.  
− The cells were not trypsinated during sub cultivation. 
− The experiments were performed at a different laboratory (AstraZeneca R&D Mölndal 
and AstraZeneca R&D Lund).  
− Experiments were performed on HEK293 cells stored at AstraZeneca R&D Lund. The 
transfected HEK293 cells used in the other experiments had been seeded, sub cultivated 
and stored at AstraZeneca Alderley Park before they were shipped to AstraZeneca R&D 
Mölndal.  
− Another amount of cells, 0.5 million cells/well, where seeded in the 24-well plates for the 
uptake studies. 
− The cells seeded in 24-well plates where treated with sodium butyrate. The culture 
medium was changed to medium containing 10 µM Na-butyrate 24 hours prior to 
experimentation. Sodium butyrate treatment is supposed to increase the expression of 
proteins (in this case the expression of OATP1B1) (Kruh, 1982). 
 
21 
MATERIALS AND METHODS 
It should be noted that the time dependence uptake studies with estradiol-17β-D-glucuronide 
(Figure 3.1 and 3.2) were performed before the conditions were optimized. Results from these 
uptake studies were satisfying (high uptake ratio), and did not indicate the need of condition 
improvements. 
2.2.2 HepaRG cells 
The differentiated HepaRG cells (passages 18 and 19) were purchased from Biopredic 
International (Rennes, France). The experiments were performed with 24-well plates (50 000 
cells seeded per well). The cells were initially grown in William’s medium E with glutamax-I 
supplemented with 10 % FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 5 μg/ml bovine 
insulin and 50 μM hydrocortisone hemisuccinate. At confluence, 2% DMSO was added to the 
medium in order to differentiate the cells into hepatocyte-like morphology. The cells were 
cultured in differentiation medium for 3 weeks before shipment to AstraZeneca R&D Mölndal. 
 
At arrival the DMSO-containing HepaRG medium was renewed. The old medium was 
removed by aspiration and 400 μl DMSO-containing HepaRG medium was added to each 
well. The cells were given 24 hours to recover. After 24 to 48 hours the medium was changed 
to basal HepaRG medium (William’s medium E with glutamax-I supplemented with 100 IU/ml 
penicillin, 100 μg/ml streptomycin, 4 μg/ml bovine insulin and 50 μM hydrocortisone 
hemisuccinate). The cells were cultured in basal HepaRG medium for 24 hours before the 
experiment was started. 
2.3 Preperation of Xenopus laevis oocytes 
Xenopus laevis oocytes microinjected with OATP1B1 cRNA and water-injected controls were 
purchased from BD Gentest Discovery Labware Inc. (BD Biosciences, Woburn, MA, USA). 
Before shipping to AstraZeneca R&D Mölndal, the oocytes were prepared the following way. 
OATP1B1 was cloned from human liver by PCR using gene-specific primers, and cDNA was 
isolated. To obtain higher expression and function of the human transporter in the oocyte, an 
oocyte expression vector was engineered by inserting Xenopus β-globin 5’ and 3’ 
untranslated region into pBluescript II KS (+) (Stratagene). cDNAs of OATP1B1 were 
subcloned into the vector with the 5’ and 3’ untranslated regions of the Xenopus β-globin 
gene flanking the insert. cRNAs were synthesized by using T3 polymerase (Stratagene). 
Oocytes were harvested and digested with collagenase D (Boehringer Mannheim). Fifty 
nanoliters of cRNA (~ 0.4 ng/nl) or water was injected individually into defolliculated oocytes. 
Oocytes were immediately transported to AstraZeneca R&D Mölndal. The temperature was 
kept between 14°C and 20°C.  
 
The oocytes were delivered in BD FalconTM 12-well plates, diluted in ND96 Buffer. Upon 
arrival the oocytes were inspected under microscope (Olympus CK2, Olympus America Inc., 
22 
MATERIALS AND METHODS 
NY, USA) to confirm viability. Dead, dying or broken oocytes were removed by a pipette, and 
the ND96 Buffer was replaced. The oocytes were stored at 14°C to 20°C. Uptake 
experiments were performed within 4 days after injection. 
2.4 Transport experiments with HEK293 cells and HepaRG cells 
2.4.1 Preparation of buffer solution and test solutions 
The buffer used in the transport experiments consisted of HBSS buffered with 25 mM HEPES 
to pH 7.4. Radiolabeled compounds were used to study the transport. The radiolabeled 
compounds were diluted directly in pre-heated buffer solution to obtain the required 
concentrations, while non-labeled compounds were dissolved in DMSO before dilution in pre-
heated buffer solution. In the concentration dependence uptake studies, each solution in the 
dilution series contained the same amount of radiolabeled compound. Experiments were 
performed with estradiol-17β-D-glucuronide on HEK293 cells to evaluate whether dilution of 
both radiolabeled and non-labeled compound gave a different Km value. 
2.4.2 Uptake experiments with HEK293 cells 
Prior to the experiments, cell confluence was examined visually under the microscope 
(Olympus CK2, Olympus America Inc., NY, USA) to assess equal growth in all cultures and 
wells. Culture medium was removed from the wells by aspiration, and the HEK293 cells were 
washed twice with 700 µl/well pre-heated (37°C) buffer solution. 250 µl pre-heated buffer 
were added to each well, and the cells were incubated for 10 minutes in a shake incubator 
(THERMOstar, BMG LabVision, Stockholm) set to a temperature of 37°C and 0 rpm. The 
experiment was started by adding 250 µl/well pre-heated test solution. During the experiment, 
the plate incubator was set to a temperature of 37°C and 450 rpm. The experiments were 
stopped at a given time by discarding the plate. The cells were immediately washed three 
times with 1000 µl/well ice cold (4°C) buffer, and lysed by adding 500 µl 0.2 M NaOH to each 
well. The plates were placed in the fridge (4°C) for approximately one hour.  
 
The experiments were performed on HEK293 cells transfected with human OATP1B1 and 
control cells (HEK293 cells transfected with the empty vector pT-REX). Active uptake was 
either expressed as the difference or ratio between uptake into HEK293/OATP1B1 and 
HEK293/pT-REX cells. A difference >0 or ratio >1 was interpreted as active, OATP-mediated 
uptake. 
 
Uptake studies were performed with three different substances; estradiol-17β-D-glucuronide, 
atorvastatin and pravastatin. Time dependent uptake was determined by measuring uptake of 
substance at six different time points over 10-15 minutes at one or two given concentrations. 
The approximate linear interval of uptake for each substance was determined by visual 
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expedition. Concentration dependent uptake was determined by measuring uptake at eight 
different concentrations at a time point within the linear interval of uptake. The concentrations 
chosen were depending on the substrate used in the experiment.  
 
The linear interval of the time dependent uptake should be determined at a low and a high 
substance concentration to assure that the uptake is linear in the whole range of 
concentrations applied in the concentration dependence uptake study. The reasons why the 
uptake studies on HEK293 cells with atorvastatin and pravastatin were performed only at low 
concentrations, were time deficiency, the high costs of these substances, and to determine 
whether this low concentration of radiolabeled substance gave an uptake detectable in the 
liquid scintillation counter. 
2.4.3 Uptake experiments with HepaRG cells 
Prior to the experiments cell confluence was examined visually under the microscope 
(Olympus CK2, Olympus America Inc., NY, USA) to assess equal growth in all wells.  
 
Uptake assay at 37°C 
Culture medium was removed from the wells by aspiration, and the HepaRG cells were 
washed twice with 700 µl/well pre-heated (37°C) buffer solution. 250 µl pre-heated buffer was 
added to each well, and the cells were incubated for 10 minutes in a shake incubator 
(THERMOstar, BMG LabVision, Stockholm) set to a temperature of 37°C and 0 rpm. The 
experiment was started by adding 250 µl/well pre-heated test solution. During the experiment, 
the plate incubator was set to a temperature of 37°C and 0 rpm. The experiments were 
stopped at a given time by discarding the plate. The cells were immediately washed three 
times with 1000 µl/well ice cold (4°C) buffer, and lysed by adding 500 µl 0.2 M NaOH to each 
well. The plates were placed in the fridge (4°C) for approximately one hour.  
 
Uptake assay at 4°C 
The 24-well plate was placed on ice. Culture medium was removed from the wells by 
aspiration, and the HepaRG cells were washed twice with 700 µl/well ice cold (4°C) buffer 
solution. 250 µl ice cold buffer was added to each well, and the cells were incubated for 10 
min. The experiment was started by adding 250 µl/well ice cold test solution. The experiments 
were stopped at a given time by discarding the plate. The cells were immediately washed 
three times with 1000 µl/well ice cold buffer, and lysed by adding 500 µl 0.2 M NaOH to each 
well. The plates were placed in the fridge (4°C) for approximately one hour.  
 
The experiments were performed on HepaRG cells at two different temperatures (37°C and 
4°C). HepaRG cells are human cells expressing a natural level of transporters, including 
OATP1B1. There exist no control cells. To determine the passive uptake into HepaRG cells, 
the experiments where performed at 4°C. At this temperature the transporters are out of 
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function. Active uptake was either expressed as the difference or ratio between uptake into 
HepaRG cells at 37°C and 4°C. A difference >0 or ratio >1 was interpreted as active, OATP-
mediated uptake. 
 
Uptake studies were performed with three different substances; estradiol-17β-D-glucuronide, 
atorvastatin and pravastatin. Time dependent uptake was determined by measuring uptake of 
substance at six different time points over 10 minutes at a given concentration. The 
approximate linear interval of uptake for each substance was determined by visual expedition. 
Concentration dependent uptake was determined by measuring uptake at eight different 
concentrations at a time point within the linear interval of uptake. The concentrations chosen 
were depending on the substrate used in the experiment. 
 
The linear interval of the time dependent uptake should be determined at a low and a high 
substance concentration to assure that the uptake is linear in the whole range of 
concentrations applied in the concentration dependence uptake study. The reasons why the 
uptake studies on HepaRG cells with atorvastatin and pravastatin were performed only at low 
concentrations and with one replicate, were the very high costs of the HepaRG cells and of 
these substances, and to determine whether the low concentration of radiolabeled substance 
gave an uptake detectable in the liquid scintillation counter. 
2.5 Transport experiments with Xenopus laevis oocytes 
2.5.1 Preparation of buffer solution and test solutions 
Sodium transport buffer from BD Biosciences was used in the first experiments with the 
oocytes. In the later experiments, transport buffer prepared at the laboratory was used. The 
buffer contained 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid/Tris, 100 mM 
NaCl, 1 mM MgCl2, 2 mM KCl, and 1 mM CaCl2, adjusted to pH 7.4. Radiolabeled 
compounds were used to study the transport. The radiolabeled compounds were diluted in 
pre-heated buffer solution to a concentration of 1 µM. Non-labeled compounds were 
dissolved in DMSO and then diluted in pre-heated buffer solution to obtain the required test 
concentrations.  
2.5.2 Uptake experiments with oocytes 
Upon experiments, the oocytes were inspected visually under microscope (Olympus CK2, 
Olympus America Inc., NY, USA) to confirm viability. Dead, dying or broken oocytes were 
removed by a pipette. Depending on the study (time dependence or concentration 
dependence), a specific number of oocytes were placed in a test tube made of glass. The 
ND96 Buffer was removed by aspiration, and the oocytes were washed three times with 3 ml 
of room temperature sodium buffer. 100 µl test solution was added after removing the sodium 
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buffer for the third time. The experiment was stopped at a given time by removing the test 
solution by aspiration. The oocytes were immediately washed three times with 3 ml ice cold 
(4°C) sodium buffer. A final aliquot of 3 ml ice cold buffer was added.  
 
The experiments were performed on oocytes injected with OATP1B1 cRNA and oocytes 
injected with water. The uptake into water injected oocytes is an expression of the passive 
uptake of substance into Xenopus laevis oocytes. Active uptake was either expressed as the 
difference or ratio between uptake into OATP1B1 cRNA injected and water injected oocytes. 
A difference >0 or ratio >1 was interpreted as active, OATP-mediated uptake. 
 
Uptake studies were performed with three different substances; estradiol-17β-D-glucuronide, 
atorvastatin and pravastatin. Time dependent uptake was determined by measuring uptake 
into three oocytes at four different time points over 20-90 minutes at a given concentration. 
The approximate linear interval of uptake for each substance was determined by visual 
expedition. Concentration dependent uptake was determined by measuring uptake into eight 
oocytes at eight different concentrations at a time point within the linear interval of uptake. 
The concentrations chosen were depending on the substrate used in the experiment.  
 
The linear interval of the time dependent uptake should be determined at a low and a high 
substance concentration to assure that the uptake is linear in the whole range of 
concentrations applied in the concentration dependence uptake study. The reason why the 
uptake studies on the oocytes were performed only at one substance concentration was the 
high costs of the oocytes. 
2.6 Analysis 
2.6.1 Liquid scintillation counting 
HEK293 cells and HepaRG cells. The 24-well plate was shaken in a plate shaker for 1 min 
at high speed. 300 µl cell lysate was transferred to a scintillation vial, and the sample was 
neutralized by adding 150 µl 0.2 M HCl. 10 ml scintillation liquid (OptiPhase HiSafe 2, Fisher 
Chemicals, UK) was added to each vial, and the sample was mixed (Vortex). The radioactivity 
was measured in a Wallac LS-counter (Wallac Win Spectral, 1414 Liquid Scintillation 
Counter, PerkinElmer).  
 
Oocytes. The oocytes were transferred to scintillation vials (one oocyte per vial). A drop of 
buffer from the last wash was placed in a separate scintillation vial to act as a negative 
control. The oocytes were lysed by adding 150 µl of 10% SDS buffer to each scintillation vial, 
and incubated on an orbital shaker for 10 minutes at room temperature. 5 ml scintillation liquid 
(OptiPhase HiSafe 2, Fisher Chemicals, UK) was added to each vial, and the sample was 
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mixed (Vortex). The radioactivity was measured in a Wallac LS-counter (Wallac Win Spectral, 
1414 Liquid Scintillation Counter, PerkinElmer).  
 
Uptake of radiolabeled compound was measured by the number of disintegrations per minute 
(dpm). In the time dependence uptake studies, the obtained data was converted into pmol/mg 
protein according to the following equation: 
proteinmg
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, where dpm is disintegrations per minute for the uptake sample, spec activity is the specific 
activity of the radiolabeled compound, and mg protein is the amount of protein per well in mg. 
      
In the experiments where both cold and warm compound were used, the total uptake was 
calculated by the following equation: 
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, where dpm is disintegrations per minute for the uptake sample, ratio cold/warm is the ratio 
between radioactive unlabeled and labeled compound, spec activity is the specific activity of 
the radiolabeled compound, and mg protein is the amount of protein per well in mg. 
2.6.2 Protein quantification 
Protein content in HEK293 cells and HepaRG cells were quantified using the method of 
Markwell (Markwell et al., 1978), which is a modified method of the Lowry procedure (Lowry 
et al., 1951). 75 μl aliquots of cell lysate were neutralized with 75 μl 0.2 M HCl. These 
samples were diluted 10x and 20x in water. The proteins were prepared by mixing 100 μl 
aliquots of lysate solution with 300 μl of Reagent solution 1 ([4% Na2CO3, 0.2M NaOH, 0.32% 
K-Na-tartrate], 2 % SDS and 4% CuSO4x5H2O in the proportion 75:75:1.5). After incubation 
for approximately 30 minutes, the samples were mixed with 30 μl of Reagent solution 2 
(Folin-Ciocalteu phenol reagent and ELGA water in the proportion 1:1), and incubated for 45 
minutes. The absorbance was measured at a wavelength of 660 nm, and protein content 
quantified in a multi-detection microplate reader, SpectraMax® M5 (Molecular Devices, 
Sunnyvale, CA, USA). The results were processed with the software program SOFTMax Pro 
v4.8 using BSA as calibration standard. 
2.6.3 mRNA quantification  
The amount of OATP1B1 mRNA in HEK293/OATP1B1 and HEK293/pT-REX cells was 
determined to compare the expression of OATP1B1 in the two cell lines. mRNA quantification 
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of hOATP1B1 in HEK293/OATP1B1 cells after treatment with sodium butyrate was also 
determined. 
 
RNA extration. 500 μl Trizol was added to each well (24-well plate) to lysate the cells, and 
total RNA from HEK293 cells was prepared according to manufacturers’ instructions 
(Invitrogen). RNA quantity was determined spectrophotometrically using a GenQuant pro 
RNA/DNA calculator (Biochrom, Cambridge, UK). cDNA was prepared from 0.5 μg of total 
RNA using the SuperScript™ III First-Strand Synthesis System for RT-PCR with random 
hexamer primers according to the manufacturer’s protocol (Invitrogen). 
 
Real-Time PCR. Real-time PCR for human OATP1B1 mRNA levels was performed by a 
7500 Sequence Detector (Applied Biosystems, Foster City, CA, USA) and manufacturer 
designed Assay on Demand for OATP1B1, MVP and PPIA. MVP and PPIA were used as 
endogenous control genes. Briefly described, the reaction mixture (25 μl per well) contained 
30 ng cDNA, 12.5 μl 2xTaqman Universal Master Mix, 1.25 μl Assay on Demand and 6.2 μl 
RNase free water. The thermal cycle had initial steps of 50°C for 2 min and a 10 min step at 
95°C followed by 40 PCR cycles of 95°C for 15 s, and finally 60°C for 1 min. Each sample 
was analyzed in triplicate and data was analyzed using the 7500 Sequence detector software 
v1.3.1 (Applied Biosystems). The amount of mRNA was determined relative to that from 
control samples. 
2.7 Data analysis 
All experiments with HEK293 and HepaRG cells were performed in triplicates (with a couple 
of exceptions), while the experiments on oocytes where performed in triplicates or more. The 
values were expressed as mean ± standard deviation.  
The active uptake was calculated as the difference in mean values of test and control 
experiments. 
 
Kinetic constants (Km and Vmax) for carrier-mediated uptake were estimated by fitting the 
calculated uptake data to the Michaelis-Menten model (equation 1.4) without weighting (XLfit4 
Excel Add-In v.4.2.2 software, Microsoft). The results from the analyses were given as point 
estimates of the Km and Vmax values ± standard error.  
28 
RESULTS 
3 RESULTS 
3.1 Time dependence uptake studies 
3.1.1 HEK293 cells 
 
Estradiol-17β-D-glucuronide 
The time course of uptake of [3H]estradiol-17β-D-glucuronide at a low concentration (3.8 nM, 
0.2 μCi/ml) by HEK293 cells is shown in Figure 3.1. The carrier-mediated uptake of estradiol-
17β-D-glucuronide in HEK293/OATP1B1 increased linearly up to approximately 300 seconds. 
The uptake ratio was 2.3 at 60 seconds, the time of incubation used in the concentration 
dependence studies. The intracellular amount of substrate at 900 seconds was 1.5% of initial 
amount in the test solution.  
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Figure 3.1 Time course of [3H]estradiol-17β-D-glucuronide (3.8 nM) uptake in HEK293 cells transfected with 
OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-
mediated uptake in the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
 
The time course of uptake of estradiol-17β-D-glucuronide at a high concentration (50 μM, 1 
μCi/ml) by HEK293 cells is shown in Figure 3.2. The carrier-mediated uptake of estradiol-17β-
D-glucuronide in HEK293/OATP1B1 increased linearly up to approximately 90 seconds. The 
uptake ratio was 3.7 at 60 seconds, the time of incubation used in the concentration 
dependence studies. 
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Figure 3.2 Time course of estradiol-17β-D-glucuronide (50 μM) uptake in HEK293 cells transfected with OATP1B1 
(■) and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-mediated uptake 
in the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
 
Atorvastatin 
The time course of uptake of [3H]atorvastatin (80 nM, 0.4 μCi/ml) by HEK293 cells is shown in 
Figure 3.3. The carrier-mediated uptake of atorvastatin in HEK293/OATP1B1 increased 
linearly up to approximately 45 seconds. The uptake ratio was 6.4 at 60 seconds, the time of 
incubation used in the concentration dependence studies. The intracellular amount of 
substrate at 600 seconds was 4.3% of initial amount in the test solution. 
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Figure 3.3 Time course of [3H]atorvastatin (80 nM) uptake in HEK293 cells transfected with OATP1B1 (■) and 
vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-mediated uptake in the 
OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=2). 
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Results from a time dependence uptake study with atorvastatin performed during the testing 
of conditions are shown in Appendix 1. The conditions used in the experiment are shown in 
the appendix. The uptake ratio in this experiment was 1.8 at 60 seconds (Figure 7.1). 
 
Pravastatin 
The time course of uptake of [3H]pravastatin (50 nM, 1 μCi/ml) by HEK293 cells is shown in 
Figure 3.4. The carrier-mediated uptake of pravastatin in HEK293/OATP1B1 increased 
linearly up to approximately 60 seconds. The uptake ratio was 13.4 at 60 seconds, the time of 
incubation used in the concentration dependence studies. The intracellular amount of 
substrate at 600 seconds was 4.9% of initial amount in the test solution.  
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Figure 3.4 Time course of [3H]pravastatin (50 nM) uptake in HEK293 cells transfected with OATP1B1 (■) and vector-
transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-mediated uptake in the 
OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=2). 
 
Results from time dependence uptake studies with pravastatin performed during the testing of 
conditions are shown in Appendix 2. The conditions used in the experiments are shown in the 
appendix. The uptake ratios in these experiments were 1.9 (Figure 7.2) and 1.6 (Figure 7.3) 
at 60 seconds. In the experiment where the cells were treated with sodium butyrate 24 hours 
prior to experimentation, the uptake ratio was 1.3 at 60 seconds (Figure 7.4).  
3.1.2 Hepa RG cells 
 
Estradiol-17β-D-glucuronide 
The time course of uptake of [3H]estradiol-17β-D-glucuronide (19 nM, 1 μCi/ml) by HepaRG 
cells at 37°C and 4°C is shown in Figure 3.5. The carrier-mediated uptake of estradiol-17β-D-
glucuronide increased linearly up to approximately 60 seconds. The uptake ratio was 2.0 at 
60 seconds, the time of incubation used in the concentration dependence studies. The 
intracellular amount of substrate at 600 seconds was 1.4% of initial amount in the test 
solution.  
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Figure 3.5 Time course of uptake of [3H]estradiol-17β-D-glucuronide (19 nM) by HepaRG cells at 37°C (■) and 4°C 
(♦). The triangles (▲) represent the carrier-mediated uptake in the HepaRG cells. Each point represents the mean ± 
S.D. (n=3). 
 
Atorvastatin 
The time course of uptake of [3H]atorvastatin (80 nM, 0.4 μCi/ml) by HepaRG cells at 37°C 
and 4°C is shown in Figure 3.6. The carrier-mediated uptake of atorvastatin increased linearly 
up to approximately 60 seconds. The uptake ratio was 9.1 at 60 seconds, the time of 
incubation used in the concentration dependence studies. The intracellular amount of 
substrate at 600 seconds was 14.4% of initial amount in the test solution. It should be noted 
that this experiment was performed with only one replicate. 
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Figure 3.6 Time course of uptake of [3H]atorvastatin (80 nM) by HepaRG cells at 37°C (■) and 4°C (♦). The triangles 
(▲) represent the carrier-mediated uptake in the HepaRG cells. Each point represents one value (n=1). 
 
32 
RESULTS 
Pravastatin 
The time course of uptake of [3H]pravastatin (50 nM, 1 μCi/ml) by HepaRG cells at 37°C and 
4°C is shown in Figure 3.7. The carrier-mediated uptake of pravastatin increased linearly up 
to approximately 300 seconds. The uptake ratio was 4.2 at 60 seconds, the time of incubation 
used in the concentration dependence studies. The intracellular amount of substrate at 600 
seconds was 0.48% of initial amount in the test solution. It should be noted that this 
experiment was performed with only one replicate. 
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Figure 3.7 Time course of uptake of [3H]pravastatin (50 nM) by HepaRG cells at 37°C (■) and 4°C (♦). The triangles 
(▲) represent the carrier-mediated uptake in the HepaRG cells. Each point represents one value (n=1). 
3.1.3 Xenopus laevis oocytes 
 
Estradiol-17β-D-glucuronide 
The time course of uptake of [3H]estradiol-17β-D-glucuronide (1 μM, 46.9 μCi/ml) by oocytes 
injected with OATP1B1 cRNA and oocytes injected with water is shown in Figure 3.8. The 
carrier-mediated uptake of estradiol-17β-D-glucuronide increased linearly up to approximately 
60 minutes. The uptake ratio was 31.7 at 60 minutes, the time of incubation used in the 
concentration dependence studies.  
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Figure 3.8 Time course of [3H]estradiol-17β-D-glucuronide (1 μM) uptake in Xenopus laevis oocytes injected with 
OATP1B1 cRNA (■) and water injected control oocytes (♦). The triangles (▲) represent the carrier-mediated uptake 
in the OATP1B1-expressing oocytes. Each point represents the mean ± S.D. (n=3). 
The reason why there is no value for the uptake in water injected oocytes at 20 minutes is 
that all the oocytes where washed away by a mistake during the experiment. From the curve 
(Figure 3.8) we can assume that the uptake in the water injected oocytes are linear up to 90 
minutes, and therefore that the carrier-mediated uptake is linear up to 60 minutes.  
 
Atorvastatin 
The time course of uptake of [3H]atorvastatin (1 μM, 5 μCi/ml) by oocytes injected with 
OATP1B1 cRNA and oocytes injected with water is shown in Figure 3.9. The carrier-mediated 
uptake of atorvastatin increased linearly up to 90 minutes. The uptake ratio was 2.7 at 60 
minutes, the time of incubation used in the concentration dependence studies. 
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Figure 3.9 Time course of [3H]atorvastatin (1 μM) uptake in Xenopus laevis oocytes injected with OATP1B1 cRNA 
(■) and water injected control oocytes (♦). The triangles (▲) represent the carrier-mediated uptake in the OATP1B1-
expressing oocytes. Each point represents the mean ± S.D. (n=3). 
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Pravastatin 
The time course of uptake of [3H]pravastatin (1 μM, 20 μCi/ml) by oocytes injected with 
OATP1B1 cRNA and oocytes injected with water is shown in Figure 3.10. The carrier-
mediated uptake of pravastatin was limited increased linearly up to 90 minutes. The uptake 
ratio was very low (1.1 at 60 minutes), indicating a limited active uptake.  
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Figure 3.10 Time course of [3H]pravastatin (1 μM) uptake in Xenopus laevis oocytes injected with OATP1B1 cRNA 
(■) and water injected control oocytes (♦). The triangles (▲) represent the carrier-mediated uptake in the OATP1B1-
expressing oocytes. Each point represents the mean ± S.D. (n=3). 
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3.2 Concentration dependence uptake studies 
3.2.1 HEK293 cells 
 
Estradiol-17β-D-glucuronide 
Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.5-75 
μM, 0.938 μCi/ml) in HEK293 cells transfected with OATP1B1 and pT-REX is shown in Figure 
3.11. Time of incubation was set to 60 seconds based on results from the time dependence 
uptake studies (Figure 3.1 and 3.2).  
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Figure 3.11 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide in HEK293 cells 
transfected with OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent 
the carrier-mediated uptake in the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
 
The active transport of estradiol-17β-D-glucuronide into HEK293/OATP1B1 was saturated. 
Kinetic analysis estimated Km and Vmax values of 5.6 ± 0.3 μM and 41.5 ± 0.7 pmol/min/mg 
protein, respectively (Figure 3.12). This Km value was approximately ten times lower than in 
similar experiments performed during testing of culturing and seeding conditions (Appendix 
3). The Km values ranged from 43.9 – 77.4 μM in the initial testing (Figure 7.5 – 7.10), but 
none of the variables tested showed a consistent change in Km value.  
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Figure 3.12 The carrier-mediated uptake of estradiol-17β-D-glucuronide in HEK293/OATP1B1 cells after fitting the 
uptake data to the modified Michaelis-Menten model (Equation 1.4) The dotted line indicates the estimated Km value; 
the substrate concentration at ½ Vmax (Figure 1.8). 
 
Results from concentration dependence uptake studies where the test solutions in the dilution 
series contained different amount of radiolabeled compound are shown in Appendix 4. Kinetic 
analysis of these results estimated Km values of 64.4 ± 4.6 μM and 48.0 ± 8.8 μM (Figure 7.11 
and 7.12). These results were similar to results from corresponding experiments where the 
test solutions in the dilution series contained the same amount of radiolabeled compound. 
 
Atorvastatin 
Concentration dependence of the initial uptake rate of atorvastatin (1-300 μM, 0.6 μCi/ml) in 
HEK293 cells transfected with OATP1B1 and pT-REX is shown in Figure 3.13. Time of 
incubation should be set to 45 seconds based on results from the time dependence uptake 
study (Figure 3.3). Due to limitations of the experimentation assay the time was set to 60 
seconds. It is practically impossible to perform the experiment with a time of incubation less 
than 60 seconds. The uptake of atorvastatin into HEK293/OATP1B1 and HEK293/pT-REX 
was both linear, and the uptake ratio was approximately 1 in the entire concentration range. 
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Figure 3.13 Concentration dependence of the initial uptake rate of atorvastatin in HEK293 cells transfected with 
OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-
mediated uptake in the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
 
Pravastatin 
Concentration dependence of the initial uptake rate of pravastatin (1-300 μM, 1 μCi/ml) in 
HEK293 cells transfected with OATP1B1 and pT-REX is shown in Figure 3.14. Time of 
incubation was set to 60 seconds based on results from the time dependence uptake study 
(Figure 3.4). The uptake into HEK293/OATP1B1 and HEK293/pT-REX was both linear, and 
the uptake ratio was approximately 1 in the entire concentration range. 
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Figure 3.14 Concentration dependence of the initial uptake rate of pravastatin in HEK293 cells transfected with 
OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-
mediated uptake in the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
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3.2.2 HepaRG cells 
 
Estradiol-17β-D-glucuronide 
Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.5-75 
μM, 0.938 μCi/ml) in HepaRG cells at 37°C and 4°C is shown in Figure 3.15.  Time of 
incubation was set to 60 seconds based on results from the time dependence uptake studies 
(Figure 3.5).  
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Figure 3.15 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide in HepaRG cells at 
37°C (■) and 4°C (♦). The triangles (▲) represent the carrier-mediated uptake in the HepaRG cells. Each point 
represents the mean ± S.D. (n=3). 
 
The active transport of estradiol-17β-D-glucuronide into HepaRG cells was saturated. Kinetic 
analysis estimated Km and Vmax values of 22.3 ± 7.1 μM and 41.9 ± 5.6 pmol/min/mg protein, 
respectively (Figure 3.16). 
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Figure 3.16 The carrier-mediated uptake of estradiol-17β-D-glucuronide in HepaRG cells after fitting the uptake data 
to the modified Michaelis-Menten model (Equation 1.4) The dotted line indicates the estimated Km value; the 
substrate concentration at ½ Vmax (Figure 1.8). 
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Atorvastatin 
Concentration dependence of the initial uptake rate of atorvastatin (1-300 μM, 0.4 μCi/ml) in 
HepaRG cells at 37°C and 4°C is shown in Figure 3.17. Time of incubation was set to 60 
seconds based on results from the time dependence uptake study (Figure 3.6).  
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Figure 3.17 Concentration dependence of the initial uptake rate of atorvastatin in HepaRG cells at 37°C (■) and 4°C 
(♦). The triangles (▲) represent the carrier-mediated uptake in the HepaRG cells. Each point represents the mean ± 
S.D. (n=3). 
 
The active transport of atorvastatin into HepaRG cells was not saturated. The uptake of 
atorvastatin was linear at both 37°C and 4°C, with an uptake ratio around 4 in the entire 
concentration range. 
 
Pravastatin 
Concentration dependence of the initial uptake rate of pravastatin (1-300 μM, 1 μCi/ml) in 
HepaRG cells at 37°C and 4°C is shown in Figure 3.18. Time of incubation was set to 60 
seconds based on results from the time dependence uptake study (Figure 3.7). The uptake of 
atorvastatin into HepaRG cells was linear at both 37°C and 4°C, and the uptake ratio was 
approximately 1 in the entire concentration range. 
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Figure 3.18 Concentration dependence of the initial uptake rate of pravastatin in HepaRG cells at 37°C (■) and 4°C 
(♦). The triangles (▲) represent the carrier-mediated uptake in the HepaRG cells. Each point represents the mean ± 
S.D. (n=3). 
3.2.3 Xenopus laevis oocytes 
 
Estradiol-17β-D-glucuronide 
Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.5-75 
μM, 46.9 μCi/ml) in oocytes injected with OATP1B1 cRNA and water is shown in Figure 3.19. 
Time of incubation was set to 60 minutes based on results from the time dependence uptake 
studies (Figure 3.8).  
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Figure 3.19 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide in Xenopus laevis 
oocytes injected with OATP1B1 cRNA (■) and water injected control oocytes (♦). The triangles (▲) represent the 
carrier-mediated uptake in the oocytes expressing OATP1B1. Each point represents the mean ± S.D. (n=8). 
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The active transport of estradiol-17β-D-glucuronide into oocytes/OATP1B1 was saturated. 
Kinetic analysis estimated Km and Vmax values of 5.9 ± 3.8 μM and 2236.1 ± 432.2 
fmol/60min/oocyte, respectively (Figure 3.20). 
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Figure 3.20 The carrier-mediated uptake of estradiol-17β-D-glucuronide in oocytes expressing OATP1B1 after fitting 
the uptake data to the modified Michaelis-Menten model (Equation 1.4) The dotted line indicates the estimated Km 
value; the substrate concentration at ½ Vmax (Figure 1.8). 
 
Atorvastatin 
Concentration dependence of the initial uptake rate of atorvastatin (1-300 μM, 5 μCi/ml) in 
oocytes injected with OATP1B1 cRNA and water is shown in Figure 3.21.  Time of incubation 
was set to 60 minutes based on results from the time dependence uptake studies (Figure 
3.9).  
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Figure 3.21 Concentration dependence of the initial uptake rate of atorvastatin in Xenopus laevis oocytes injected 
with OATP1B1 cRNA (■) and water injected control oocytes (♦). The triangles (▲) represent the carrier-mediated 
uptake in the oocytes expressing OATP1B1. Each point represents the mean ± S.D. (n=6-7). 
 
The uptake of atorvastatin into oocytes/OATP1B1 and control oocytes was both linear, and 
the uptake ratio was approximately 1 in the entire concentration range.   
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Pravastatin 
Concentration dependence of the initial uptake rate of pravastatin (1-250 μM, 20 μCi/ml) in 
oocytes injected with OATP1B1 cRNA and water is shown in Figure 3.22.  Time of incubation 
was set to 60 minutes based on results from the time dependence uptake studies (Figure 
3.10).  
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Figure 3.22 Concentration dependence of the initial uptake rate of pravastatin in Xenopus laevis oocytes injected 
with OATP1B1 cRNA (■) and water injected control oocytes (♦). The triangles (▲) represent the carrier-mediated 
uptake in the oocytes expressing OATP1B1. Each point represents the mean ± S.D. (n=6-7). 
 
The active transport of pravastatin into oocytes/OATP1B1 was saturated. Kinetic analysis 
estimated Km and Vmax values of 54.8 ± 31.4 μM and 791.9 ± 162.5 fmol/60min/oocyte, 
respectively (Figure 3.23). 
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Figure 3.23 The carrier-mediated uptake of pravastatin in oocytes expressing OATP1B1 after fitting the uptake data 
to the modified Michaelis-Menten model (Equation 1.4.) The dotted line expresses the estimation of the Km value; the 
substrate concentration at ½ Vmax (Figure 1.8). 
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3.3 mRNA quantification 
Results from the comparison of total amount of OATP1B1 mRNA in HEK293/OATP1B1 cells, 
HEK293/pT-REX cells, and HEK293/OATP1B1 cells treated with Na-butyrate, are shown in 
Figure 3.24. The amount of OATP1B1 mRNA in the HEK/pT-REX cells was not detectable. 
Treatment with sodium butyrate gave no significant change (p ~ 0.21) in the amount of 
OATP1B1 mRNA in the HEK293/OATP1B1 cells. 
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Figure 3.24 Relative amount of OATP1B1 mRNA in HEK293/OATP1B1 cells treated with sodium butyrate and in 
HEK293/pT-REX cells, compared to HEK293/OATP1B1 cells. Values are calculated with untreated 
HEK293/OATP1B1 cells as reference and results are shown as mean ± S.D. (n=3). The amount of OATP1B1 mRNA 
is normalized to PPIA mRNA and MVP mRNA. 
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4  DISCUSSION 
4.1 Methodological considerations 
Transfected HEK293 cells is the most applied system for determination of whether a 
compound is a substrate of OATP1B1, while estradiol-17β-D-glucuronide is the best 
recognized substrate of the OATP1B1 transporter. In the preliminary experiments, the 
intention was to reproduce results from prior uptake studies on HEK293 cells with the 
estradiol-17β-D-glucuronide (Table 4.1). However, the estimated Km value of the initial 
experiments (~ 70 μM) was approximately 10-fold higher than previously published values (~ 
4-8 μM) (Table 4.1). The results showed that changes in culture medium, amount of medium 
and cells seeded per flask, frequency of splitting, trypsination, laboratory, and cells sub 
cultivated at different AstraZeneca sites, had a limited impact on the estimated Km value of 
estradiol-17β-D-glucuronide (~ 45–65 μM). In a single experiment, a Km value of 5.6 μM was 
obtained (Figure 3.12). In this experiment, it was observed reduced cell confluency in the 
wells before experimentation. The amount of cells seeded three days prior to experimentation 
was the same as in previous studies, but these specific cells (from a certain vial) were 
observed to grow very slowly during the period of splitting and seeding in flasks prior to 
seeding in 24-well plates.  
 
Reduced cell confluency is consistent with increased surface area per cell exposed to 
substrate solution. This could explain the more rapid increase in uptake at low concentrations, 
compared to the uptake in confluent cell layers, and the resulting low Km value. Reduced 
amount of cells seeded per well had previously been tested in the process of optimising the 
method. However, reduction from 0.5 million to 0.3 million cells seeded per well had limited 
impact on the estimated Km value of estradiol-17β-D-glucuronide. The impact of cell 
confluency in uptake studies with HEK293 cells should be further studied. 
 
In the studies of Iwai et al. and König et al., the HEK293 cells were treated with sodium 
butyrate prior to experimentation (Iwai et al., 2004; Konig et al., 2000). Sodium butyrate is 
supposed to induce the mRNA expression, resulting in increased protein expression (Kruh, 
1982). However, sodium butyrate could also induce cell toxicity (Louis et al., 2004). The 
mRNA level in HEK293 cells after sodium butyrate treatment was reduced rather than 
increased, which indicates that the cell toxicity induced by sodium butyrate was more 
important than the induction of OATP1B1.  
 
The intracellular amount of substrate after uptake was low compared to the total amount in 
the test solution (<5% in all except from one experiment). It is assumed that the whole 
extracellular amount of substrate is available for intracellular uptake. However, there is a 
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possibility that substrate adherence to cell membranes and/or plastic walls of the wells could 
result in decreased concentration in the test solution. Overall substrate recovery should 
therefore be performed to ensure that the added test concentration actually is obtained during 
experimentation.  
 
Of economical reasons, the time dependence uptake studies were performed at low 
concentrations, with one exception. Studies at a higher concentration would have been useful 
to ensure linearity in the whole concentration range applied in the concentration dependence 
uptake studies. In transporter-mediated uptake, factors causing deviation from linearity of the 
curve are lack of substance or lack of co-factors. At low concentrations, lack of substrate is 
relevant, while lack of co-factors is relevant at high concentrations. In uptake experiments at 
low concentrations, the lack of substrate will probably occur before the lack of co-factors. 
Therefore, the time point chosen based on time dependence uptake studies at low 
concentrations, should also be within the linear interval of uptake at high concentrations. 
Time-dependent uptake of estradiol-17β-D-glucuronide in HEK293 cells was tested at low 
and high concentrations, and the linear intervals were similar (Figure 3.1 and Figure 3.2). 
 
In the concentration dependence uptake studies, radioactive compounds were diluted with 
non-labeled compounds. There is a theoretical possibility that the affinity of the compound to 
the transporter vary between labeled and non-labeled compound. For estradiol-17β-D-
glucuronide, dilution series containing different amount of labeled compound, and dilution 
series containing the same amount of labeled compound, were applied in parallel 
experiments. Results from these studies showed no significant difference in uptake kinetics, 
indicating that the labeled and non-labeled form of estradiol-17β-D-glucuronide exhibit similar 
transporter affinity. Theoretically, labeling could influence the affinity of other substrates, 
depending on the substrate-transporter interactions and which part of the molecule that is 
labeled.  
4.2 Transport studies 
The purpose of the present study was to compare OATP1B1-mediated uptake kinetics in 
three in vitro models. For the probe substrate estradiol-17β-D-glucuronide, the results from 
time- and concentration dependence studies were consistent (Table 4.1). The experiments 
showed active uptake of the probe substrate in both time- and concentration dependence 
studies. The active uptake of estradiol-17β-D-glucuronide was saturated in all three systems, 
and the estimated Km values were within the range of prior publications on similar systems 
(Table 4.1). 
 
On the contrary, the results from the uptake studies with atorvastatin and pravastatin were not 
consistent between and within the models. Atorvastatin showed active uptake in time 
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dependence uptake studies in all three models. However, in the concentration dependence 
uptake studies atorvastatin exhibited no active uptake in the overexpressed models, while a 
non-saturated active uptake was demonstrated in the HepaRG cells. These results are not in 
accordance with literature data on HEK293 cells, where a saturated, active uptake of 
atorvastatin (Km value 12.4 μM) has been reported (Table 4.1). 
Table 4.1 Summary of the results from time dependence and concentration dependence uptake studies with three 
different substrates. Estimated Km values from the concentration dependence studies are compared with literature 
values for the same substrate in similar models. There are no prior publications concerning uptake kinetics in 
HepaRG cells. The Km values referred to are from studies of human hepatocytes (HH) or rat hepatocytes (rH).  
Substrate In vitro 
model 
Active 
uptake,  
time dep 
Active 
uptake,  
conc dep 
Km (μM) Km (μM) prior 
published 
E17bG HEK293 Yes Yes 5.6 8.2 1  
4.3 2  
E17bG HepaRG Yes Yes 22.3 10.2 3(HH) 
E17bG Oocytes Yes Yes 5.9 9.7 3 
3.0 4 
Atorvastatin HEK293 Yes No - 12.4 5 
Atorvastatin HepaRG Yes Yes No saturation - 
Atorvastatin Oocytes Yes No - - 
Pravastatin HEK293 Yes No - 85.7 5 
33.7 6 
Pravastatin HepaRG Yes No - 10.2 3(HH) 
29.1 7(rH) 
16.5 8(rH)  
Pravastatin Oocytes No Yes 54.8 13.7 3  
Abbreviations: conc dep; concentration dependence, E17bG; estradiol-17β-D-glucuronide, HH; human hepatocytes, 
rH; rat hepatocytes, time dep; time dependence. 
1 (Konig et al., 2000)  5 (Kameyama et al., 2005) 
2 (Iwai et al., 2004)   6 (Hsiang et al., 1999) 
3 (Nakai et al., 2001)  7 (Yamazaki et al., 1993) 
4 (Bossuyt et al., 1996)  8 (Nezasa et al., 2003) 
 
 
For pravastatin, the observations in the time- and concentration dependence uptake studies 
were contradictory in all models. In the time dependence studies on HEK293 and HepaRG 
cells, pravastatin exhibited an active uptake, while only a limited active uptake was 
demonstrated in the oocytes. The concentration dependence uptake studies showed no 
active uptake in HEK293 and HepaRG cells, and a saturated, active uptake in oocytes with an 
estimated Km value of 54.8 μM. This value is relatively consistent with Km values reported on 
pravastatin in various models (~ 12-86 μM) (Table 4.1), but relatively high compared to 
another Km value reported on oocytes (~ 14 μM) (Table 4.1). 
 
The inconsistent results from the studies on atorvastatin and pravastatin regarding active 
uptake could possibly be explained by variations in the passive diffusion of the substances. 
The logD values of pravastatin and atorvastatin are –0.47 and 1.34, respectively (Ishigami et 
al., 2001), compared to –2.78 for estradiol-17β-D-glucuronide (predicted by C-Lab; ACDlogD 
with pKa correction library v10), indicating that the statins exhibit passive diffusion to a greater 
extent than estradiol-17β-D-glucuronide. When the active uptake of a substance is low 
compared to the passive diffusion (Figure 1.7B), the models would not be sufficiently sensitive 
to separate the active uptake from the passive uptake. The inconsistent results in the 
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experiments with pravastatin and atorvastatin could therefore reflect insufficient sensitivity of 
the models in determining OATP1B1-mediated uptake of lipophilic substrates with greater 
passive than active transport.  
 
HepaRG cells are expressing a multiplicity of transporters and enzymes (Aninat et al., 2006; 
Le Vee et al., 2006). Functional expression analysis of HepaRG cells have shown substantial 
mRNA levels and functional activity of the uptake transporters OATP-C, OATP-B, OCT1 and 
NTCP, the efflux transporters P-gp, MRP2, MPR3 and BCRP (Le Vee et al., 2006), and the 
enzymes CYP1A2, 2C9, 2D6, 2E1 and 3A4 (Aninat et al., 2006). Atorvastatin is reported to 
be substrate of P-gp, MRP2 and CYP3A4 (Chen et al., 2005; Lau et al., 2006; Lennernas, 
2003), while pravastatin is substrate of MRP2, P-gp, BCRP and OATP-B (Hirano et al., 2005; 
Kobayashi et al., 2003; Matsushima et al., 2005; Sasaki et al., 2002). The unsaturated active 
uptake of atorvastatin, and the inconsistent results between the time- and concentration 
dependence uptake studies on pravastatin, could therefore be explained by influence of other 
active processes than OATP1B1-mediated uptake in HepaRG cells. If the purpose of a study 
is to determine the uptake mediated specifically by OATP1B1, the effects of specific inhibitors 
of OATP1B1 on the uptake kinetics, or the effects of siRNA knock down or knock out (Tian et 
al., 2004; Tian et al., 2005), should be determined. 
 
The present study compared three different in vitro models. In addition to issues related to 
uptake kinetics, the models exhibit differences in practical importance. Of the overexpressed 
systems, transfected HEK293 cells are cheap and easy to seed, sub cultivate and handle. 
HEK293 cells therefore represent a promising model, but the impact of cell confluency and 
substrate lipophilicity on uptake kinetics needs to be evaluated. Xenopus laevis oocytes are 
expensive, and the uptake studies are more time consuming and tedious compared to the cell 
lines. cRNA injected oocytes as transport models could still be useful tools in studies on 
newly discovered transporters, when no stably transfected cell line is available, but they are 
not fitted for large-scale transport studies. HepaRG cells, expressing a natural level of 
OATP1B1, are extremely expensive (715 Euro per 24-well plate). In addition, studies in 
HepaRG cells require the use of specific inhibitors or siRNA to estimate net OATP1B1-
mediated uptake. HepaRG cells are, however, an interesting model in studies of the 
quantitative importance of different kinetic processes of a drug in hepatocytes. 
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5 SUMMARY AND CONCLUSION 
 
In this study, three different in vitro models expressing the membrane drug transporter 
OATP1B1 were compared using three known OATP1B1 substrates. Estradiol-17β-D-
glucuronide was the only substrate showing consistent results between the models, and 
between time- and concentration dependence uptake studies within the same model. Results 
from the studies with atorvastatin and pravastatin were generally inconsistent between the 
models. Furthermore, concentration dependence and saturation of uptake was difficult to 
obtain even if a time dependent uptake was recorded. The inconsistent results with 
atorvastatin and pravastatin could be due to the higher lipophilicity and greater extent of 
passive diffusion compared to estradiol-17β-D-glucuronide. It could therefore be hypothesized 
that when a substrate exhibits greater passive diffusion than active uptake, the models would 
not be sufficiently sensitive to separate the active uptake from the passive uptake. As drugs 
are generally more lipophilic than estradiol-17β-D-glucuronide, none of the in vitro transport 
models studied are expected to be appropriate for routine screening of new drugs as possible 
substrates for OATP1B1.  
 
Of the three in vitro models studied, transfected HEK293 cells are exhibiting most practical 
advantages as a transport model for large-scale transport studies. They are cheap, easy to 
seed and sub cultivate, and easy to handle and work with in uptake studies. However, the 
impact of seeding density, cell confluency and substrate lipophilicity should be further studied 
to improve the method.  
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7 APPENDIX 
7.1 Appendix 1 
Results from experiments on HEK293 cells using cell culturing conditions different from the 
conditions described in chapter 2.2.1: 
Culture medium:  500 ml D-MEM/F-12 (1:1) (1x) liquid with GlutaMAXTM I, 50 ml heat 
inactivated FCS, 2.5 ml PEST and 5 ml Geneticin (50 mg/ml) was used.  
Splitting:  1 million cells in 75 cm2 flasks with 25 ml culture medium, grown for 7 days 
before new splitting/seeding. 
Trypsinated:  No 
Seeding density:  0.5 million cells/well, 24-well plates 
Cells:  AstraZeneca R&D Mölndal (AstraZeneca Alderley Park) 
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Figure 7.1 Time course of [3H]atorvastatin (80 nM, 0.4 μCi/ml) uptake in HEK293 cells transfected with OATP1B1 (■) 
and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-mediated uptake in 
the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
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7.2 Appendix 2 
Results from experiments on HEK293 cells using cell culturing conditions different from the 
conditions described in chapter 2.2.1: 
Culture medium: 500 ml D-MEM/F-12 (1:1) (1x) liquid with GlutaMAXTM I, 50 ml heat 
inactivated FCS, 2.5 ml PEST and 5 ml Geneticin (50 mg/ml) was used.  
Splitting:  1 million cells in 75 cm2 flasks with 25 ml culture medium, grown for 7 days 
before new splitting/seeding. 
Trypsinated:  No 
Seeding density:  0.5 million cells/well, 24-well plates 
Cells:  AstraZeneca R&D Mölndal (AstraZeneca Alderley Park) 
 
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Time (min)
U
pt
ak
e 
(fm
ol
/m
g 
pr
ot
ei
n)
HEK293/pT-REX
HEK293/OATP1B1
Carrier-mediated uptake
 
Figure 7.2 Time course of [3H]pravastatin (50 nM, 1 μCi/ml) uptake in HEK293 cells transfected with OATP1B1 (■) 
and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-mediated uptake in 
the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
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Figure 7.3 Time course of [3H]pravastatin (50 μM, 1 μCi/ml) uptake in HEK293 cells transfected with OATP1B1 (■) 
and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-mediated uptake in 
the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
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Results from experiments on HEK293 cells using cell culturing conditions different from the 
conditions described in chapter 2.2.1: 
Culture medium:  500 ml D-MEM/F-12 (1:1) (1x) liquid with GlutaMAXTM I, 50 ml heat 
inactivated FCS, 2.5 ml PEST and 5 ml Geneticin (50 mg/ml) was used.  
Splitting:  1 million cells in 75 cm2 flasks with 25 ml culture medium, grown for 7 days 
before new splitting/seeding. 
Trypsinated:  No 
Seeding density:  0.5 million cells/well, 24-well plates 
Cells:  AstraZeneca R&D Mölndal (AstraZeneca Alderley Park) 
Sodium butyrate:  The cells seeded in 24-well plates were treated with 10 µM Na-butyrate 24 
hours prior to experimentation. 
0
10
20
30
40
50
60
70
80
90
100
0 60 120 180 240 300 360 420 480 540 600
Time (sec)
U
pt
ak
e 
(fm
ol
/m
g 
pr
ot
ei
n)
HEK293/pT-REX
HEK293/OATP1B1
Carrier-mediated uptake
 
Figure 7.4 Time course of [3H]pravastatin (50 nM, 1 μCi/ml) uptake in HEK293 cells transfected with OATP1B1 (■) 
and vector-transfected control cells, HEK293/pT-REX (♦). The triangles (▲) represent the carrier-mediated uptake in 
the OATP1B1-expressing HEK293 cells. Each point represents the mean ± S.D. (n=3). 
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7.3 Appendix 3 
Results from experiments on HEK293 cells using cell culturing conditions different from the 
conditions described in chapter 2.2.1: 
Culture medium:  500 ml D-MEM/F-12 (1:1) (1x) liquid with GlutaMAXTM I, 50 ml heat 
inactivated FCS, 2.5 ml PEST and 5 ml Geneticin (50 mg/ml) was used.  
Splitting:  1 million cells in 75 cm2 flasks with 25 ml culture medium, grown for 7 days 
before new splitting/seeding. 
Trypsinated:  No 
Seeding density:  0.5 million cells/well, 24-well plates 
Cells:  AstraZeneca R&D Mölndal (AstraZeneca Alderley Park) 
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Figure 7.5 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.53-100 µM, 1.59 
µCi/ml) in HEK293 cells transfected with OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX (♦). The 
triangles (▲) represent the carrier-mediated uptake in the OATP1B1-expressing HEK293 cells. Each point 
represents the mean ± S.D. (n=3). 
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Figure 7.6 The carrier-mediated uptake of estradiol-17β-D-glucuronide in HEK293/OATP1B1 cells after fitting the 
uptake data to the modified Michaelis-Menten model (Equation 1.4) The dotted line expresses the estimation of the 
Km value; the substrate concentration at ½ Vmax (Figure 1.8). Kinetic analysis estimated Km and Vmax values of 77.4 ± 
4.6 μM and 570.7 ± 19.0 pmol/min/mg protein, respectively. 
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Figure 7.7 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.5-200 µM, 1.06 
µCi/ml) in HEK293 cells transfected with OATP1B1 (■) and vector-transfected control cells, Hek293/pT-REX (♦). The 
triangles (▲) represent the carrier-mediated uptake in the OATP1B1-expressing HEK293 cells. Each point 
represents the mean ± S.D. (n=3).  
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Figure 7.8 The carrier-mediated uptake of estradiol-17β-D-glucuronide in HEK293/OATP1B1 cells after fitting the 
uptake data to the modified Michaelis-Menten model (Equation 1.4) The dotted line expresses the estimation of the 
Km value; the substrate concentration at ½ Vmax (Figure 1.8). Kinetic analysis estimated Km and Vmax values of 71.7 ± 
5.6 μM and 803.6 ± 27.4 pmol/min/mg protein, respectively. 
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Results from experiments on HEK293 cells using cell culturing conditions different from the 
conditions described in chapter 2.2.1: 
Laboratory:  The experiments were performed at AstraZeneca R&D Lund with cells grown 
and seeded there. 
Cells:  AstraZeneca R&D Lund 
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Figure 7.9 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.5-200 µM, 1.06 
µCi/ml) in HEK293 cells transfected with OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX (♦). The 
triangles (▲) represent the carrier-mediated uptake in the OATP1B1-expressing HEK293 cells. Each point 
represents the mean ± S.D. (n=3). 
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Figure 7.10 The carrier-mediated uptake of estradiol-17β-D-glucuronide in HEK293/OATP1B1 cells after fitting the 
uptake data to the modified Michaelis-Menten model (Equation 1.4) The dotted line expresses the estimation of the 
Km value; the substrate concentration at ½ Vmax (Figure 1.8). Kinetic analysis estimated Km and Vmax values of 43.9 ± 
8.1 μM and 761.6 ± 53.6 pmol/min/mg protein, respectively. 
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7.4 Appendix 4 
Results from experiments on HEK293 cells using different amount of radioactive compound in 
the test solutions in the dilution series: 
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Figure 7.11 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.78-100 µM, 0.037-
4.69 µCi/ml) in HEK293 cells transfected with OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX 
(♦). The triangles (▲) represent the carrier-mediated uptake in the OATP1B1-expressing HEK293 cells. Each point 
represents the mean ± S.D. (n=3). 
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Figure 7.12 The carrier-mediated uptake of estradiol-17β-D-glucuronide in HEK293/OATP1B1 cells after fitting the 
uptake data to the modified Michaelis-Menten model (Equation 1.4) The dotted line expresses the estimation of the 
Km value; the substrate concentration at ½ Vmax (Figure 1.8). Kinetic analysis estimated Km and Vmax values of 64.4 ± 
4.6 μM and 788.8 ± 29.4 pmol/min/mg protein, respectively. 
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Figure 7.13 Concentration dependence of the initial uptake rate of estradiol-17β-D-glucuronide (0.78-150 µM, 0.037-
7.035 µCi/ml) in HEK293 cells transfected with OATP1B1 (■) and vector-transfected control cells, HEK293/pT-REX 
(♦). The triangles (▲) represent the carrier-mediated uptake in the OATP1B1-expressing HEK293 cells. Each point 
represents the mean ± S.D. (n=3). 
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Figure 7.14 The carrier-mediated uptake of estradiol-17β-D-glucuronide in HEK293/OATP1B1 cells after fitting the 
uptake data to the modified Michaelis-Menten model (Equation 1.4) The dotted line expresses the estimation of the 
Km value; the substrate concentration at ½ Vmax (Figure 1.8). Kinetic analysis estimated Km and Vmax values of 48.0 ± 
8.8 μM and 634.1 ± 50.3 pmol/min/mg protein, respectively. 
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